NASDAQ:CNCE

Concert Pharmaceuticals Announces Pricing of Public Offering

Retrieved on: 
Thursday, June 2, 2022
Biotechnology, Pharmaceutical, Health, Clinical Trials, New Drug Application, Madison Avenue, DCE, Jefferies, Security (finance), Mizuho Securities, Telephone, U.S. Securities and Exchange Commission, Private Securities Litigation Reform Act, Medication, Alopecia areata, Sale, Mizuho, Prospectus, NASDAQ, SEC, Truist Financial, Jefferies Group, Attention, Compte rendu, CNCE, Deuterium, Life insurance

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced the pricing of an underwritten public offering of 10,000,000 shares of its common stock at a public offering price of $4.75 per share.

Key Points: 
  • Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced the pricing of an underwritten public offering of 10,000,000 shares of its common stock at a public offering price of $4.75 per share.
  • The gross proceeds to Concert, before deducting underwriting discounts and commissions and estimated offering expenses payable by Concert, are expected to be approximately $47.5 million.
  • Concert has granted the underwriters a 30-day option to purchase up to an additional 1,500,000 shares of common stock at the public offering price, less underwriting discounts and commissions.
  • The offering is expected to close on or about June 6, 2022, subject to the satisfaction of customary closing conditions.

Concert Pharmaceuticals Announces Proposed Public Offering of Common Stock

Retrieved on: 
Tuesday, May 31, 2022
Health, FDA, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Telephone, Jefferies, CNCE, U.S. Securities and Exchange Commission, Jefferies Group, NASDAQ, Private Securities Litigation Reform Act, Deuterium, DCE, Attention, Alopecia areata, Medication, Compte rendu, Sale, Madison Avenue, Truist Financial, SEC, Prospectus, Security (finance)

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it intends to offer and sell 10,000,000 shares of its common stock in an underwritten registered public offering.

Key Points: 
  • Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it intends to offer and sell 10,000,000 shares of its common stock in an underwritten registered public offering.
  • The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
  • Jefferies and Truist Securities are acting as joint book-running managers for the proposed offering.
  • Concert intends to grant the underwriters a 30-day option to purchase up to an additional 1,500,000 shares of common stock sold in the offering on the same terms and conditions.

Concert Pharmaceuticals Reports Positive Topline Results for First CTP-543 Phase 3 Clinical Trial in Alopecia Areata

Retrieved on: 
Monday, May 23, 2022
Health, FDA, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Department, Disease, CNCE, Yale School of Medicine, Patient, NASDAQ, Adult, Hope, FDA, SALT, Hair, Week, Medication, Alopecia areata, PRO, Scalp, Degenerative disease, Pharmaceutical industry

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced positive topline results from its recently completed Phase 3 clinical trial, THRIVE-AA1, evaluating its oral investigational medicine CTP-543 in adult patients with moderate to severe alopecia areata, an autoimmune disorder that results in patchy or complete scalp hair loss.

Key Points: 
  • Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced positive topline results from its recently completed Phase 3 clinical trial, THRIVE-AA1, evaluating its oral investigational medicine CTP-543 in adult patients with moderate to severe alopecia areata, an autoimmune disorder that results in patchy or complete scalp hair loss.
  • There is a great need for treatments for this challenging disease, and the results from the THRIVE-AA1 trial suggest that CTP-543 may potentially provide an important therapy for treating alopecia areata.
  • We are extremely grateful to the patients and teams of clinical research professionals who participate in our trials, said James V. Cassella, Ph.D., Chief Development Officer of Concert Pharmaceuticals.
  • Patients enrolled in THRIVE-AA1 were required to have at least 50 percent scalp hair loss due to alopecia areata, as measured by SALT.

Concert Pharmaceuticals Reports First Quarter 2022 Financial Results

Retrieved on: 
Thursday, May 5, 2022
Science, Other Science, Biotechnology, Research, Pharmaceutical, Health, Clinical Trials, Other Health, Alopecia areata, CNCE, Severity, Net international investment position, Hair loss, Investment, Concert, NASDAQ, SALT, Company, NDA, Food, Software, Research, Patient, Autoimmune disease, Webcast, FDA, International, Regulation of tobacco by the U.S. Food and Drug Administration, New Drug Application, Hair, Adult, Breakthrough therapy, Investor, Medication, Degenerative disease, The First Half of My Life, Exercise, Music, Pharmaceutical industry, Cryptocurrency

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today reported financial results for the first quarter of 2022.

Key Points: 
  • Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today reported financial results for the first quarter of 2022.
  • The THRIVE-AA2 topline results are expected to follow soon thereafter, in the third quarter of 2022.
  • The Company expects to report topline results from the first CTP-543 Phase 3 trial, THRIVE-AA1, in the second quarter of 2022.
  • ET to provide an update on the Company and discuss its first quarter 2022 financial results.

Concert Pharmaceuticals to Report First Quarter 2022 Results on May 5, 2022

Retrieved on: 
Thursday, April 28, 2022
Biotechnology, General Health, Pharmaceutical, Health, Alopecia areata, International, LinkedIn, Software, CNCE, Medication, DCE, Twitter, Investor, Company, Concert, Webcast, NASDAQ, Deuterium, Pharmaceutical industry

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will report its financial results for the first quarter of 2022, on Thursday, May 5, 2022, before the U.S. financial markets open.

Key Points: 
  • Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will report its financial results for the first quarter of 2022, on Thursday, May 5, 2022, before the U.S. financial markets open.
  • ET to discuss its first quarter 2022 financial results and provide a business update.
  • Individuals interested in participating in the call should dial (855) 354-1855 (U.S. and Canada) or (484) 365-2865 (International).
  • Concert Pharmaceuticals is a clinical stage biopharmaceutical company that is developing small molecule drugs that it discovered through the application of its DCE Platform (deuterated chemical entity platform).

Concert Pharmaceuticals Reports 2021 Financial Results and Provides Company Update

Retrieved on: 
Thursday, March 3, 2022
Health, General Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, NDA, Celgene, Research, Regulation of tobacco by the U.S. Food and Drug Administration, Patient, Investment, RA, Adult, Software, Hair, Investor, Food, Breakthrough therapy, Net international investment position, International, CNCE, FDA, Agitation, New Drug Application, Alopecia areata, Webcast, Severity, Sale, Company, SALT, Medication, Concert, Autoimmune disease, The First Half of My Life, Lists of diseases, Hair loss, Exercise, Otsuka Pharmaceutical, NASDAQ, Music, Pharmaceutical industry, Schizophrenia

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today reported financial results for the year ended December 31, 2021.

Key Points: 
  • Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today reported financial results for the year ended December 31, 2021.
  • The Company expects to report topline results from the first CTP-543 Phase 3 trial, THRIVE-AA1, in the second quarter of 2022.
  • ET to provide an update on the Company and discuss financial results for the year ended December 31, 2021.
  • A live webcast of the financial results may be accessed in the Investors section of the Companys website at www.concertpharma.com .

Concert Pharmaceuticals to Report Fourth Quarter 2021 Results on March 3, 2022

Retrieved on: 
Thursday, February 24, 2022
Health, Infectious Diseases, Clinical Trials, General Health, Pharmaceutical, Biotechnology, Investor, Webcast, Twitter, International, NASDAQ, Medication, DCE, Company, CNCE, Alopecia areata, LinkedIn, Deuterium, Pharmaceutical industry

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will report its financial results for the fourth quarter of 2021, on Thursday, March 3, 2022, before the U.S. financial markets open.

Key Points: 
  • Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will report its financial results for the fourth quarter of 2021, on Thursday, March 3, 2022, before the U.S. financial markets open.
  • ET to discuss its fourth quarter 2021 financial results and provide a business update.
  • Individuals interested in participating in the call should dial (855) 354-1855 (U.S. and Canada) or (484) 365-2865 (International).
  • Concert Pharmaceuticals is a clinical stage biopharmaceutical company that is developing small molecule drugs that it discovered through the application of its DCE Platform (deuterated chemical entity platform).